Any current/future new fundraising through debt or equity?

There is no explicit mention of any current or future fundraising through debt or equity in the provided transcript. The management did not discuss plans for acquisitions or major financing activities in the near term. Mukund Kabra mentioned that decisions like buybacks or dividends are taken by the Board, with dividend increases planned, but buyback is not considered efficient. No comments were made about raising fresh equity or debt capital during the call. The focus appears to be on organic growth, R&D expansion, and scaling up operations rather than fundraising. Overall, there is no indica

Any current/future capex/capital investment/strategic investment?

Advanced Enzyme Technologies is expanding its R&D capabilities, aiming to increase R&D capacity by threefold. A new R&D center is being built in Nasik, expected to be fully operational by the end of next year, facilitating gradual ramp-up in R&D activities. Current R&D expenditure for 6 months was INR143 million (vs. INR121 million last year), with capex of INR18 million (up from INR5 million last year). Investments are focused on hiring new scientists, expanding infrastructure, and acquiring new equipment, addressing space constraints limiting hiring. The company is also investing in novel en

Future growth expectations in sales/revenue/volumes?

The company expects single-digit revenue growth for the full financial year '25, revised down from earlier double-digit growth guidance. Growth in India is expected to be muted or flat this year, largely due to delays in biocatalyst sales and competition in key product segments like serratiopeptidase. The US business is seeing continuous upward momentum, with expectations of better performance in the second half, particularly from Evoxx and Nutraceutical segments. Europe and other international markets are expected to show moderate improvements in the latter half of the year. The busin

Future growth expectations in earnings/operating earnings/profits/EPS?

Company expects single-digit revenue growth for the full financial year 2025, revised from earlier hopes of double-digit growth due to some deferred sales and market challenges. EBITDA growth is typically 2x to 3x the revenue growth; however, with single-digit revenue growth, EBITDA growth is also expected to moderate accordingly. EBITDA margin guidance is around 30% to 33% as revenue picks up in second half; Q2 margin was subdued at 29% due to lower top line and higher freight costs. Profitability is expected to improve in second half, with the US business showing stronger growth prospe

Current/ Expected Orderbook/ Pending Orders?

The company operates primarily on a purchase order basis without long-term contracts. The number of purchase orders (POs) at any given time is typically not more than INR 10-12 crores. Customers often undergo trials and validations for new products, which can delay order finalization. Orders expected from trials are sometimes deferred, possibly affecting growth timelines (e.g., some business expected in FY25 may shift to FY26). Mukund Kabra mentioned the difficulty in providing exact orderbook numbers due to the nature of business. The outlook and order expectations are based more on anticipat

IN US

Sale is live|00:00:00left today

Advanced Enzyme Technologies LtdQ3 FY24Pharmaceuticals & Biotechnology

Advanced Enzyme Technologies Ltd Q3 FY24 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹374P/E: 25.4Market Cap: ₹4.1K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 4

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 4

→The company expects single-digit revenue growth for the full financial year '25, revised down from earlier double-digit growth guidance.
→Growth in India is expected to be muted or flat this year, largely due to delays in biocatalyst sales and competition in key product segments like serratiopeptidase.
→The US business is seeing continuous upward momentum, with expectations of better performance in the second half, particularly from Evoxx and Nutraceutical segments.
→Europe and other international markets are expected to show moderate improvements in the latter half of the year.
→The business operates mainly on a purchase order basis, without long-term contracts, so visibility is limited; growth depends on ongoing customer trials and new product approvals.
→Longer-term growth beyond FY '25 depends heavily on expanding R&D capabilities to develop more products and biocatalyst molecules.
→Achieving consistent 25% growth is considered difficult without significant ramp-up in R&D and product pipeline expansion.

Margin guidance

Category 3

→Company expects single-digit revenue growth for the full financial year 2025, revised from earlier hopes of double-digit growth due to some deferred sales and market challenges.
→EBITDA growth is typically 2x to 3x the revenue growth; however, with single-digit revenue growth, EBITDA growth is also expected to moderate accordingly.
→EBITDA margin guidance is around 30% to 33% as revenue picks up in second half; Q2 margin was subdued at 29% due to lower top line and higher freight costs.
→Profitability is expected to improve in second half, with the US business showing stronger growth prospects and some recovery expected from deferred sales.
→EPS and PAT are expected to reflect the same moderation, with prior quarters showing a PAT margin around 22%-23%.
→No near-term large acquisitions planned that might significantly impact earnings.
→Long-term growth depends on R&D expansion and new product development to enhance scale and margins.

3 more insights locked — sign up free to unlock

Fundraise plans

→There is no explicit mention of any current or future fundraising through debt or equity in the provided transcript.
→The management did not discuss plans for acquisitions or major financing activities in the near term.
→Mukund Kabra mentioned that decisions like buybacks or dividends are taken by the Board, with dividend increases planned, but buyback is not considered efficient.
→No comments were made about raising fresh equity or debt capital during the call.
→The focus appears to be on organic growth, R&D expansion, and scaling up operations rather than fundraising.
→Overall, there is no indication of any immediate or planned debt or equity fundraising from the management during this earnings call.

Order book

→The company operates primarily on a purchase order basis without long-term contracts.
→The number of purchase orders (POs) at any given time is typically not more than INR 10-12 crores.
→Customers often undergo trials and validations for new products, which can delay order finalization.
→Orders expected from trials are sometimes deferred, possibly affecting growth timelines (e.g., some business expected in FY25 may shift to FY26).
→Mukund Kabra mentioned the difficulty in providing exact orderbook numbers due to the nature of business.
→The outlook and order expectations are based more on anticipated additions of new customers and their potential business rather than fixed long-term orders.
→Some orders related to Evoxx have been received, with POs expected to pan out over the entire year.
→Shipment and delivery delays (e.g., due to freight and logistics issues) have impacted the timing of order realization.

Capex plans

Yes

→Advanced Enzyme Technologies is expanding its R&D capabilities, aiming to increase R&D capacity by threefold.
→A new R&D center is being built in Nasik, expected to be fully operational by the end of next year, facilitating gradual ramp-up in R&D activities.
→Current R&D expenditure for 6 months was INR143 million (vs. INR121 million last year), with capex of INR18 million (up from INR5 million last year).
→Investments are focused on hiring new scientists, expanding infrastructure, and acquiring new equipment, addressing space constraints limiting hiring.
→The company is also investing in novel enzyme and biocatalyst development with a long-term strategic focus, though some details are kept confidential for IP reasons.
→No immediate plans for acquisitions or buybacks were mentioned; acquisition in the US is not expected within the next year.
→Freight cost issues due to geopolitical factors led to an impact of approx. INR1.5 crores in the quarter, indicating attention to logistics investments.

How does Advanced Enzyme Technologies Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

1Advanced Enzyme Technologies Ltd

Rev 4Mar 3

See full Pharmaceuticals & Biotechnology sector rankings

Want more stocks like Advanced Enzyme Technologies Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio